Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
July 2025
The global miRNA tools and services market size is calculated at US$ 417.69 in 2024, grew to US$ 498.34 million in 2025, and is projected to reach around US$ 2399.94 million by 2034. The market is expanding at a CAGR of 19.34% between 2025 and 2034.
The miRNA tools and services market is expanding quickly due to the growing need for sophisticated therapeutic and diagnostic tools to treat patients. To investigate the function of miRNA in biological processes, illnesses, and the identification of specific genes, these techniques and services include next-generation sequencing, microarray, quantification, and bioinformatics. miRNA, or short non-coding RNA molecules, are important for controlling post-transcriptional levels of gene expression and disease pathogenesis. Personalized medicine development and early illness diagnosis can also benefit from the use of miRNA as biomarkers.
| Metric | Details |
| Market Size in 2025 | USD 498.34 Million |
| Projected Market Size in 2034 | USD 2399.94 Million |
| CAGR (2025 - 2034) | 19.34% |
| Leading Region | North America share by 44% |
| Market Segmentation |
By Product and Service Type, By Technology, By Application, By End User, By Region |
| Top Key Players | Thermo Fisher Scientific, QIAGEN, Illumina, Agilent Technologies, Bio-Rad Laboratories, Takara Bio, Horizon Discovery (now Revvity), PerkinElmer / Revvity, Norgen Biotek, Exiqon (now part of QIAGEN), GeneCopoeia, Bioline (Meridian Bioscience), System Biosciences (SBI), Miltenyi Biotec, BioCat GmbH, LC Sciences, CD Genomics, GenoSensor Corporation, Omega Bio-Tek, Abcam |
The tools and services market facilitates the analysis, characterization, and measurement of miRNA, small, non-coding RNA molecules involved in gene regulation, and is referred to as the miRNA tools and services market. MiRNA tools and services help extract, quantify, and analyze miRNAs, shedding light on how miRNAs function in various biological processes and diseases. The combination of multi-omics approaches with miRNA technology is creating a new market development potential for miRNA products and services. Since miRNA technologies and services are crucial for regulating cancer by affecting carcinogenesis, progression, and therapy resistance, the rising incidence of cancer is driving the market for them.
It has previously been said that machine learning, a branch of artificial intelligence, is a helpful instrument for analyzing big, complicated data sets. For instance, the technique may be applied to the analysis of miRNA expression patterns or the identification of transcription start sites in genome sequences in the field of genomics. There are tremendous prospects for creating microRNA therapies thanks to cutting-edge technologies like CRISPR/Cas, which targets microRNA genes, and artificial intelligence-based models, which anticipate microRNA targets.
The Rising Number of miRNA-Based Clinical Trials
Current studies and clinical trials are expanding the use of miRNA in preclinical and clinical research. A growing body of research suggests that miRNAs may be important as biomarkers for pathogenic conditions, modulators of treatment resistance, or therapeutic agents for nearly all human diseases. Therefore, the increase in clinical studies evaluating the efficacy of miRNA in treating various chronic illnesses is a key factor driving the market's growth.
High Cost of Tools and Services
The time-consuming testing procedures and expensive equipment required to identify miRNA significantly increase the overall value of the research, due to the high cost of kits and chemicals, which raises the overall cost of research and testing. Utilizing cutting-edge technologies like microarrays and NGS increases the cost of research, as highly qualified experts are required to operate this equipment precisely and conduct the tests according to the protocol.
Adoption of Biomarkers
The importance of microRNAs as non-invasive biomarkers is growing, and researchers and the medical community are increasingly recognizing the crucial role of biomarkers in the early detection and monitoring of disease conditions. The stability of microRNAs in physiological fluids makes them an ideal tool for representing and diagnosing diseases. Growing awareness is consequently driving the demand for microRNA-based assays that will help provide essential information on sickness situations and treatment responses.
By product and service type, the miRNA detection & quantification tools segment led the miRNA tools and services market in 2024. Accurate assessment of miRNA expression is necessary to comprehend how miRNAs operate in cellular processes and human illnesses. qRT-PCR is a widely used and effective technique for measuring miRNA. miRNA identification can be crucial for an early, accurate diagnosis, determining how well a patient is responding to treatment, and improving the patient's prospects of survival.
By product and service type, the miRNA sequencing & bioinformatics services segment is anticipated to grow at the highest CAGR during the upcoming timeframe. By attaching to mRNA, miRNA sequencing services enable the identification of unique functions and traits associated with gene expression. There are increasing opportunities to learn more about miRNA biology and its potential applications in medicine as the field of miRNA sequencing advances. Over the past decade, the volume of miRNA data has grown significantly with the introduction of next-generation sequencing, necessitating the development of innovative bioinformatics techniques for handling and archiving this additional data. To better understand the functions of miRNAs, new methods for mining these sequencing datasets have been created.
By technology, the qRT-PCR segment held the largest share of the miRNA tools and services market in 2024. miRNA with High Specificity miRNA and the qRT-PCR detection kit using the appropriate reagents, the QRT-PCR Master Mix Detection Kit polyadenylates microRNAs (miRNAs) and then synthesizes first-strand cDNA from these tailed miRNAs. The highest specificity is provided by qPCR detection reagents and a new PCR enzyme formulation. When great accuracy and precision are needed, the qRT-PCR technique is frequently employed to validate the results of screening tests.
By technology, the next-generation sequencing (NGS) segment is estimated to witness the highest CAGR during 2025-2034. The full complement of miRNAs found in an RNA sample may now be sequenced thanks to next-generation sequencing methods. Through expression profiling, sequence isoform identification, new miRNA prediction, and the identification of putative mRNA target molecules, the information gathered from these sequencing investigations may be utilized to describe miRNA expression and function.
By application, the cancer research & oncology segment dominated as dominant in the miRNA tools and services market in 2024. MicroRNAs, or miRNAs, are now significant regulators in cancer biology that affect carcinogenesis, progression, and resistance to therapy. They are positioned as appealing targets or therapeutic tools because of their ability to affect a range of tumor-suppressive and oncogenic pathways. Both progress and difficulties are evident in current clinical investigations, underscoring the need for advanced strategies to optimize specificity and minimize toxicity.
By application, the biomarker discovery & translational research segment is estimated to be the fastest-growing during the predicted timeframe. Circulating and exosomal miRNAs have also been proposed as possible diagnostic markers for a variety of diseases and malignancies. Recent developments have strengthened the potential of miRNAs as sensitive and specific biomarkers for early cancer detection. Additionally, they have demonstrated considerable potential as diagnostic tools for malignancies that are challenging to detect, such as those with enigmatic symptoms or challenging diagnostic criteria. Translational research on microRNAs (miRNAs) aims to use our knowledge of these small non-coding RNA molecules to develop new methods for diagnosing and treating human diseases.
By end-user, the academic & research institutions segment held the major share of the miRNA tools and services market in 2024. miRNA is crucial in different types of research, and academic & research institutions have used many for various purposes. Major research areas that utilize miRNA are biological research, disease biomarkers, therapeutic areas, translational research, and bioinformatics. Various tools and services are used by such institutions for conduction the research, including NGS, PCR, etc.
By end-user, the clinical diagnostic labs segment is anticipated to achieve the highest growth during the forecast period. Sensitive and efficient diagnostic techniques are desperately needed for a number of illnesses. Potential instruments for identifying these illnesses include biomarkers like microRNAs (miRNAs). It has been determined that circulating miRNAs are promising non-invasive indicators for precise diagnosis, prediction of disease progression, and response to therapy. Numerous miRNA panels are already available for clinical usage, at least for cancer and other disorders, and they have demonstrated the possibility for early diagnosis.
North America dominated the miRNA tools and services market share by 44% in 2024 due to its robust research infrastructure, significant investments in genomics, and high rate of collaborations between academic institutions and biotechnology companies. Because of the region's strong government initiatives and emphasis on precision medicine, the market is growing. Furthermore, the presence of major industry players and a deliberate attempt to integrate cutting-edge technologies further solidify North America's position in the miRNA tools and services market.
As genomics research advances, there is a growing trend of genetic and genomic testing in the U.S., both within and outside of clinics. The government agencies that regulate genetic testing include the Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and the Federal Trade Commission (FTC).
Genomics may be used to efficiently solve urgent global concerns such as early diagnosis and the discovery of rare illnesses. Canada is among the world leaders in genome research and its application in several industries, including healthcare, thanks to the more than $1.6 billion that Genome Canada has provided over the past 20 years to fund large-scale applied and translational genomics.
Asia Pacific is estimated to host the fastest-growing miRNA tools and services market during the forecast period. The presence of a large target population, the quicker adoption of various technologies, the existence of multiple startups in tandem with the development of healthcare infrastructure, and the existence of high-unmet clinical needs are some of the factors that are anticipated to benefit key manufacturers in the region from growth opportunities.
The growth of genetic testing has accelerated in China due to the rapid advancement of technology techniques. There are a lot of genomics firms in China right now. Beijing Genomics Institute, Berry Genomics, Anouta, Da'an Gene Company, and Nuohe Zhiyuan Company are a few of them.
The biotechnology sector has experienced significant growth over the last decade, and India is now one of the world's top 12 biomanufacturers. The establishment of India's own genetic data collection is a significant achievement that will facilitate future scientific and medical advancements. At IBDC, 10,000 whole genome samples have been maintained and are now available for use in local and international research. This data collecting will be a great help to genome research, which will advance healthcare and individualized medication.
Europe is expected to grow significantly in the miRNA tools and services market during the forecast period. The increase in investments in the biotechnology and pharmaceutical industries is a key driver of the market for miRNA tools and services. Additionally, the development of proteomics, genomics, and cancer research infrastructure, together with the increasing number of granted patents for miRNA biomarkers, is expected to propel the market.
There is now coverage of next-generation sequencing analysis (NGS) in Germany. Germany will begin formally implementing a genetic medicine policy in January 2024. This pilot program, SGB V §64e, has the potential to transform healthcare in Germany by allowing personalized care for everybody.
From groundbreaking discoveries in fundamental research to their translation into clinical practice and improved patient outcomes, the UK has made a significant contribution to this rapidly evolving and intriguing field. The NHS has committed to scanning 500,000 entire genomes by 2023–2024 to accelerate diagnosis and enhance outcomes (NHS England). Furthermore, there is a global Direct-to-Consumer Genetic Testing Market (DCGT) for products that provide information on a range of topics, including ancestry or personalized wellness and medical advice based on a customer's genetic information.
In July 2024, according to a brain study, microRNAs are probably involved in neurodegenerative and mental illnesses. According to the study's principal author, Aliza Wingo, this is the first investigation to date to pinpoint microRNAs implicated in the emergence of neurodegenerative and mental disorders. Wingo works as a staff psychiatrist at the VA Northern California Health Care System and is a professor in the Department of Psychiatry and Human Behavior at UC Davis. (Source - Medical Xpress)
By Product and Service Type
By Technology
By Application
By End User
By Region
July 2025
July 2025
July 2025
July 2025